{"name":"Excyte Biopharma Ltd","slug":"excyte-biopharma-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"YKST02","genericName":"YKST02","slug":"ykst02","indication":"Other","status":"phase_1"},{"name":"YK012","genericName":"YK012","slug":"yk012","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"YKST02","genericName":"YKST02","slug":"ykst02","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YK012","genericName":"YK012","slug":"yk012","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNbnBHaVFCMDNjZE41YS0xREMycU5jUWtuV2d3RlZicVZPVTNlaWtTdko3V3NVY2U2bXJsaXgxclNJMDAzbnEtVlJscF94aG1RT2pMT2UzVmhfNjA1amhsdWF1cEdZazBCNnZEX3ZQaUNzeWlBdmgxYzRNb2dPLUJhUktyVllQY2UwYjVqVklGOWRSMzhzUERhd0JlQ1lzRlBtQ2paZXNJaURtLWF4Nk1ZdjZPdU4xVmY4U1FSV0hOVmRlam96dXdWS1hUYWVBNmJ2ZWNNVlM3Y28zUE1YMkxvU09hX05HUkpBOGJvRlJTNG9FMUdQT2Q0aVl3bS02V0d1aXlJ?oc=5","date":"2026-04-02","type":"pipeline","source":"Barchart.com","summary":"Non-Hodgkin Lymphoma Treatment Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Non-Hodgkin Lymphoma Treatment Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPYmdmamhtb2R6VEYtNXl5LW44QkpWRjE2Unl2d1lFSXUzNzNMM1hfc2FwUnctZEljR3NsNmVyanFJZWF5d0ZBM0Q4VmNMbUMweU9aeV92c3RYMGo2eE0zczhBd1BQRzZxN3Rndk5UYjQ4OXVDc2pteGl3cDNkUkJvRG9VcE1HQ1cteTdLSnZBZXVscEhjaWV0NVdoSXJWbkk1SERPWHVtdG01M0dQNDB1VGZxMm9MNlF1ck1wVk1WM1RtUWt3VHRiWEREeDNVNjdDMFpaZzBLaGk0dDdsb0dTX0hsSW9lWXBmbko0QkpfQnY?oc=5","date":"2025-06-03","type":"trial","source":"BioPharma APAC","summary":"Excyte Doses First Patient in Global Trial of YK012, the First T Cell Engager for Primary Membranous Nephropathy - BioPharma APAC","headline":"Excyte Doses First Patient in Global Trial of YK012, the First T Cell Engager for Primary Membranous Nephropathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNU3laQ0pOaEVnZGRUZHBOTU5ENjVPR1VIVTRpY3NRTTlXd05nSVlZMWU5bU1fWUlsVlBzYXB6NGZMUmdxZVZUZWVCa1FYMjl5U09GczBrVkVuNmk5bnBQSTNSZnNabS1wZmxjMkJNQl9XaDBidmhhc2Jtb1hQM1hFWTFCSzVzYmhaUnhIY282SEZCaTJjR18zZjNEZ21kV29TUEpDUVF0MjlKdy1nVF90TVNEa0xyWXpYSkFYbXNCYmlnU0FveXRpdXZZQmFTRUtFdmVLcWNlb1BuTGhGY2gtYlBZMA?oc=5","date":"2025-01-10","type":"deal","source":"BioPharma APAC","summary":"Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront - BioPharma APAC","headline":"Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}